Latest findings in phosphate homeostasis

Kidney International

Volumn 75, Issue 9, 2009, Pages 882-889

  Prié, Dominique ^a,b,e   Torres, Pablo Urẽa ^c   Friedlander, Gérard ^b,d  

^a AP HP   (France)

^b INSERM   (France)

^c Clinique du Landy   (France)

^d Service de Physiologie et Radio isotopes   (France)

^e Hpital Necker Enfants Malades   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; PHOSPHATE; PHOSPHATE TRANSPORTER; SODIUM PHOSPHATE COTRANSPORTER 2A; SODIUM PHOSPHATE COTRANSPORTER 2C;

ARTICLE; BONE DEMINERALIZATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; NONHUMAN; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PHOSPHATE BALANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; PROTEIN FUNCTION; SECONDARY HYPERPARATHYROIDISM; SIGNAL TRANSDUCTION; SOFT TISSUE CALCIFICATION;

FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HOMEOSTASIS; HUMANS; KIDNEY; MUTATION; PHOSPHATE TRANSPORT PROTEINS; PHOSPHATES;

EID: 64949097327     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.643     Document Type: Article

References (118)

1. Prie D, Beck L, Urena P et al Recent findings in phosphate homeostasis Curr Opin Nephrol Hypertens 2005; 14 318-324.
2. Block GA, Hulbert-Shearon TE, Levin NW et al Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 1998; 31 607-617.
3. Tonelli M, Sacks F, Pfeffer M et al Relation between serum phosphate level and cardiovascular event rate in people with coronary disease Circulation 2005; 112 2627-2633.
4. Prie D, Beck L, Friedlander G et al Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization Curr Opin Nephrol Hypertens 2004; 13 675-681.
5. Murer H, Hernando N, Forster I et al Proximal tubular phosphate reabsorption: molecular mechanisms Physiol Rev 2000; 80 1373-1409.
6. Ohkido I, Segawa H, Yanagida R et al Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney Pflugers Arch 2003; 446 106-115.
7. Beck L, Karaplis AC, Amizuka N et al Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities Proc Natl Acad Sci USA 1998; 95 5372-5377.
8. Prie D, Huart V, Bakouh N et al Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter N Engl J Med 2002; 347 983-991.
9. Chau H, El-Maadawy S, McKee MD et al Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2 J Bone Miner Res 2003; 18 644-657.
10. Lapointe JY, Tessier J, Paquette Y et al NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak Kidney Int 2006; 69 2261-2267.
11. Bergwitz C, Roslin NM, Tieder M et al SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis Am J Hum Genet 2006; 78 179-192.
12. Juppner H. Novel regulators of phosphate homeostasis and bone metabolism. Ther Apher Dial 2007; 11(Suppl 1): S3-S22.
13. Lorenz-Depiereux B, Benet-Pages A, Eckstein G et al Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3 Am J Hum Genet 2006; 78 193-201.
14. Ichikawa S, Sorenson AH, Imel EA et al Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria J Clin Endocrinol Metab 2006; 91 4022-4027.
15. Segawa H, Kaneko I, Takahashi A et al Growth-related renal type II Na/Pi cotransporter J Biol Chem 2002; 277 19665-19672.
16. Bacconi A, Virkki LV, Biber J et al Renouncing electroneutrality is not free of charge: switching on electrogenicity in a Na+-coupled phosphate cotransporter Proc Natl Acad Sci USA 2005; 102 12606-12611.
17. Tenenhouse HS, Martel J, Gauthier C et al Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c Am J Physiol 2003; 285 F1271-F1278.
18. Feild JA, Zhang L, Brun KA et al Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine Biochem Biophys Res Commun 1999; 258 578-582.
19. Xu H, Bai L, Collins JF et al Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2) Genomics 1999; 62 281-284.
20. Katai K, Miyamoto K, Kishida S et al. Regulation of intestinal Na+- dependent phosphate co-transporters by a low-phosphate diet and 1,25- dihydroxyvitamin D3. Biochem J 1999; 343(Part 3): 705-712.
21. Corut A, Senyigit A, Ugur SA et al Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis Am J Hum Genet 2006; 79 650-656.
22. Biber J, Custer M, Werner A et al. Localization of NaPi-1, a Na/Pi cotransporter, in rabbit kidney proximal tubules. II Localization by immunohistochemistry Pflugers Arch 1993; 424 210-215.
23. Busch AE, Schuster A, Waldegger S et al Expression of a renal type I sodium/phosphate transporter (NaPi-1) induces a conductance in Xenopus oocytes permeable for organic and inorganic anions Proc Natl Acad Sci USA 1996; 93 5347-5351.
24. Collins JF, Bai L, Ghishan FK The SLC20 family of proteins: dual functions as sodium-phosphate cotransporters and viral receptors Pflugers Arch 2004; 447 647-652.
25. Salaun C, Rodrigues P, Heard JM Transmembrane topology of PiT-2, a phosphate transporter-retrovirus receptor J Virol 2001; 75 5584-5592.
26. Giachelli CM Vascular calcification mechanisms J Am Soc Nephrol 2004; 15 2959-2964.
27. Forster IC, Hernando N, Biber J et al Proximal tubular handling of phosphate: a molecular perspective Kidney Int 2006; 70 1548-1559.
28. Zhao N, Tenenhouse HS Npt2 gene disruption confers resistance to the inhibitory action of parathyroid hormone on renal sodium-phosphate cotransport Endocrinology 2000; 141 2159-2165.
29. Sitara D, Kim S, Razzaque MS et al Genetic evidence of serum phosphateindependent functions of FGF-23 on bone PLoS Genet 2008; 4 e1000154.
30. Segawa H, Yamanaka S, Onitsuka A et al Parathyroid hormonedependent endocytosis of renal type IIc Na-Pi cotransporter Am J Physiol 2007; 292 F395-F403.
31. Gisler SM, Stagljar I, Traebert M et al Interaction of the type IIa Na/Pi cotransporter with PDZ proteins J Biol Chem 2001; 276 9206-9213.
32. Mahon MJ, Donowitz M, Yun CC et al Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling Nature 2002; 417 858-861.
33. Shenolikar S, Voltz JW, Minkoff CM et al Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting Proc Natl Acad Sci USA 2002; 99 11470-11475.
34. Cunningham R, Xiaofei E, Steplock D, Shenolikar S et al Defective PTH regulation of sodium-dependent phosphate transport in NHERF-1-/- renal proximal tubule cells and wild-type cells adapted to low-phosphate media Am J Physiol 2005; 289 F933-F938.
35. Capuano P, Bacic D, Roos M et al Defective coupling of apical PTH receptors to phospholipase C prevents internalization of the Na+- phosphate cotransporter NaPi-IIa in Nherf1-deficient mice Am J Physiol Cell Physiol 2007; 292 C927-C934.
36. Mahon MJ, Cole JA, Lederer ED et al Na+/H+ exchanger-regulatory factor 1 mediates inhibition of phosphate transport by parathyroid hormone and second messengers by acting at multiple sites in opossum kidney cells Mol Endocrinol 2003; 17 2355-2364.
37. Iida-Klein A, Guo J, Xie LY et al Truncation of the carboxyl-terminal region of the rat parathyroid hormone (PTH)/PTH-related peptide receptor enhances PTH stimulation of adenylyl cyclase but not phospholipase C J Biol Chem 1995; 270 8458-8465.
38. Karim Z, Ge'rard B, Bakouh N et al NHERF1 mutations and responsiveness of renal parathyroid hormone N Engl J Med 2008; 359 1128-1135.
39. Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35: 1192-1199.
40. Liu S, Zhou J, Tang W et al Pathogenic role of Fgf23 in Hyp mice Am J Physiol Endocrinol Metab 2006; 291 E38-E49.
41. Sitara D, Razzaque MS, Hesse M et al Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice Matrix Biol 2004; 23 421-432.
42. Ferrari SL, Bonjour JP, Rizzoli R Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men J Clin Endocrinol Metab 2005; 90 1519-1524.
43. Gupta A, Winer K, Econs MJ et al FGF-23 is elevated by chronic hyperphosphatemia J Clin Endocrinol Metab 2004; 89 4489-4492.
44. Kolek OI, Hines ER, Jones MD et al 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renalgastrointestinal- skeletal axis that controls phosphate transport Am J Physiol Gastrointest Liver Physiol 2005; 289 G1036-G1042.
45. Liu S, Tang W, Zhou J et al Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D J Am Soc Nephrol 2006; 17 1305-1315.
46. Burnett SM, Gunawardene SC, Bringhurst FR et al Regulation of Cterminal and intact FGF-23 by dietary phosphate in men and women J Bone Miner Res 2006; 21 1187-1196.
47. Saito H, Maeda A, Ohtomo S et al Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo J Biol Chem 2005; 280 2543-2549.
48. Antoniucci DM, Yamashita T, Portale AA Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men J Clin Endocrinol Metab 2006; 91 3144-3149.
49. White KE, Carn G, Lorenz-Depiereux B et al Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23 Kidney Int 2001; 60 2079-2086.
50. White KE, Jonsson KB, Carn G et al The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting J Clin Endocrinol Metab 2001; 86 497-500.
51. Larsson T, Marsell R, Schipani E et al Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis Endocrinology 2004; 145 3087-3094.
52. Shimada T, Mizutani S, Muto T et al Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia Proc Natl Acad Sci USA 2001; 98 6500-6505.
53. Yamazaki Y, Okazaki R, Shibata M et al Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia J Clin Endocrinol Metab 2002; 87 4957-4960.
54. Saito H, Kusano K, Kinosaki M et al Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production J Biol Chem 2003; 278 2206-2211.
55. Shimada T, Hasegawa H, Yamazaki Y et al FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis J Bone Miner Res 2004; 19 429-435.
56. Shimada T, Muto T, Urakawa I et al Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo Endocrinology 2002; 143 3179-3182.
57. Shimada T, Urakawa I, Yamazaki Y et al FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa Biochem Biophys Res Commun 2004; 314 409-414.
58. Inoue Y, Segawa H, Kaneko I et al Role of the vitamin D receptor in FGF23 action on phosphate metabolism Biochem J 2005; 390 325-331.
59. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al The parathyroid is a target organ for FGF23 in rats J Clin Invest 2007; 117 4003-4008.
60. Krajisnik T, Bjorklund P, Marsell R et al Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells J Endocrinol 2007; 195 125-131.
61. Shimada T, Kakitani M, Yamazaki Y et al Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism J Clin Invest 2004; 113 561-568.
62. Razzaque MS, Sitara D, Taguchi T et al Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process FASEB J 2006; 20 720-722.
63. Sitara D, Razzaque MS, St-Arnaud R et al Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals Am J Pathol 2006; 169 2161-2170.
64. Yamazaki Y, Tamada T, Kasai N et al Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23 J Bone Miner Res 2008; 23 1509-1518.
65. Ichikawa S, Guigonis V, Imel EA et al. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact FGF23 concentrations. J Clin Endocrinol Metab 2007.
66. Ichikawa S, Lyles KW, Econs MJ A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive J Clin Endocrinol Metab 2005; 90 2420-2423.
67. Ichikawa S, Lyles KW, Econs MJ A Novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive J Clin Endocrinol Metab 2005; 90 2420-2423.
68. Larsson T, Yu X, Davis SI et al A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis J Clin Endocrinol Metab 2005; 90 2424-2427.
69. Garringer HJ, Fisher C, Larsson TE et al The role of mutant UDP-N-acetylalpha- D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis J Clin Endocrinol Metab 2006; 91 4037-4042.
70. Frishberg Y, Ito N, Rinat C et al Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23 J Bone Miner Res 2007; 22 235-242.
71. Araya K, Fukumoto S, Backenroth R et al A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis J Clin Endocrinol Metab 2005; 90 5523-5527.
72. Chefetz I, Heller R, Galli-Tsinopoulou A et al A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification Hum Genet 2005; 118 261-266.
73. Hesse M, Frohlich LF, Zeitz U et al Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice Matrix Biol 2007; 26 75-84.
74. Stubbs JR, Liu S, Tang W et al Role of hyperphosphatemia and 1,25- dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice J Am Soc Nephrol 2007; 18 2116-2124.
75. Kuro-o M, Matsumura Y, Aizawa H et al Mutation of the mouse klotho gene leads to a syndrome resembling ageing Nature 1997; 390 45-51.
76. Tsujikawa H, Kurotaki Y, Fujimori T et al Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system Mol Endocrinol 2003; 17 2393-2403.
77. Kurosu H, Ogawa Y, Miyoshi M et al Regulation of fibroblast growth factor-23 signaling by klotho J Biol Chem 2006; 281 6120-6123.
78. Urakawa I, Yamazaki Y, Shimada T et al Klotho converts canonical FGF receptor into a specific receptor for FGF23 Nature 2006; 444 770-774.
79. Segawa H, Yamanaka S, Ohno Y et al Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice Am J Physiol 2007; 292 F769-F779.
80. Li SA, Watanabe M, Yamada H et al Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice Cell Struct Funct 2004; 29 91-99.
81. Tohyama O, Imura A, Iwano A et al Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides J Biol Chem 2004; 279 9777-9784.
82. Chang Q, Hoefs S, van der Kemp AW et al The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel Science 2005; 310 490-493.
83. Kurosu H, Yamamoto M, Clark JD et al Suppression of aging in mice by the hormone klotho Science 2005; 309 1829-1833.
84. Yamamoto M, Clark JD, Pastor JV et al Regulation of oxidative stress by the anti-aging hormone klotho J Biol Chem 2005; 280 38029-38034.
85. Gutierrez O, Isakova T, Rhee E et al Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease J Am Soc Nephrol 2005; 16 2205-2215.
86. Larsson T, Nisbeth U, Ljunggren O et al Circulating concentration of FGF- 23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers Kidney Int 2003; 64 2272-2279.
87. Weber TJ, Liu S, Indridason OS et al Serum FGF23 levels in normal and disordered phosphorus homeostasis J Bone Miner Res 2003; 18 1227-1234.
88. Urena Torres P, Friedlander G, de Vernejoul MC et al Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients Kidney Int 2008; 73 102-107.
89. Fliser D, Kollerits B, Neyer U et al Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study J Am Soc Nephrol 2007; 18 2600-2608.
90. Kazama JJ, Sato F, Omori K et al Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients Kidney Int 2005; 67 1120-1125.
91. Nakanishi S, Kazama JJ, Nii-Kono T et al Serum fibroblast growth factor- 23 levels predict the future refractory hyperparathyroidism in dialysis patients Kidney Int 2005; 67 1171-1178.
92. Gutierrez OM, Mannstadt M, Isakova T et al Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis N Engl J Med 2008; 359 584-592.
93. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: tertiary 'Hyper-Phosphatoninism'? Kidney Int 2006; 70: 1486-1494.
94. Koh N, Fujimori T, Nishiguchi S et al Severely reduced production of klotho in human chronic renal failure kidney Biochem Biophys Res Commun 2001; 280 1015-1020.
95. Arking DE, Atzmon G, Arking A et al Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity Circ Res 2005; 96 412-418.
96. Arking DE, Becker DM, Yanek LR et al KLOTHO allele status and the risk of early-onset occult coronary artery disease Am J Hum Genet 2003; 72 1154-1161.
97. Arking DE, Krebsova A, Macek Sr M et al Association of human aging with a functional variant of klotho Proc Natl Acad Sci USA 2002; 99 856-861.
98. Rhee EJ, Oh KW, Lee WY et al The differential effects of age on the association of KLOTHO gene polymorphisms with coronary artery disease Metabolism 2006; 55 1344-1351.
99. Riancho JA, Valero C, Hernandez JL et al Association of the F352V variant of the Klotho gene with bone mineral density Biogerontology 2007; 8 121-127.
100. Ogata N, Matsumura Y, Shiraki M et al Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women Bone 2002; 31 37-42.
101. Kawano K, Ogata N, Chiano M et al Klotho gene polymorphisms associated with bone density of aged postmenopausal women J Bone Miner Res 2002; 17 1744-1751.
102. Lu L, Katsaros D, Wiley A et al Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression Cancer Invest 2008; 26 185-192.
103. Ikushima M, Rakugi H, Ishikawa K et al Anti-apoptotic and antisenescence effects of klotho on vascular endothelial cells Biochem Biophys Res Commun 2006; 339 827-832.
104. Sugiura H, Yoshida T, Tsuchiya K et al Klotho reduces apoptosis in experimental ischaemic acute renal failure Nephrol Dial Transplant 2005; 20 2636-2645.
105. Fukino K, Suzuki T, Saito Y et al Regulation of angiogenesis by the aging suppressor gene klotho Biochem Biophys Res Commun 2002; 293 332-337.
106. Shimada T, Takeshita Y, Murohara T et al Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse Circulation 2004; 110 1148-1155.
107. Dobbie H, Unwin RJ, Faria NJ et al Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption Nephrol Dial Transplant 2008; 23 730-733.
108. Rowe PS, Kumagai Y, Gutierrez G et al MEPE has the properties of an osteoblastic phosphatonin and minhibin Bone 2004; 34 303-319.
109. Rowe PS, de Zoysa PA, Dong R et al MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia Genomics 2000; 67 54-68.
110. Argiro L, Desbarats M, Glorieux FH et al Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone Genomics 2001; 74 342-351.
111. Bresler D, Bruder J, Mohnike K et al Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets J Endocrinol 2004; 183 R1-R9.
112. Liu S, Guo R, Simpson LG et al Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX J Biol Chem 2003; 278 37419-37426.
113. Liu S, Rowe PS, Vierthaler L et al Phosphorylated acidic serine-aspartaterich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity J Endocrinol 2007; 192 261-267.
114. Martin A, David V, Laurence JS et al Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP Endocrinology 2008; 149 1757-1772.
115. Rowe PS, Garrett IR, Schwarz PM et al Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP) Bone 2005; 36 33-46.
116. Liu S, Brown TA, Zhou J et al Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia J Am Soc Nephrol 2005; 16 1645-1653.
117. Feng JQ, Ward LM, Liu S et al Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism Nat Genet 2006; 38 1310-1315.
118. Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis Nat Genet 2006; 38 1248-1250.